lactobacillus helveticus

Cell therapyexperimental

Lactobacillus helveticus is a gram-positive, lactic-acid producing, rod-shaped bacterium of the genus Lactobacillus. It is most commonly used in the production of American Swiss cheese and Emmental cheese, but is also sometimes used in making other styles of cheese, such as Cheddar, Parmesan, Romano, provolone, and mozzarella. The primary function of L. helveticus culture is to prevent bitterness and produce nutty flavors in the final cheese. In Emmental cheese production, L. helveticus is used in conjunction with a Propionibacterium culture, which is responsible for developing the holes through production of carbon dioxide gas. — Wikipedia

Clinical trial activity

24 trials · 33 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
8
Phase 3
5
Phase 4
3

Earliest trial started Dec 1, 2006 (NCT00655798)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lactobacillus helveticus
  • lactobacillus helveticus r0052
  • l. helveticus r0052

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07165977N/AJan 25, 2024National Science Centre, Poland, SWPS University
NCT05567653N/ASep 21, 2022Poznan University
NCT04997057N/ASep 15, 2021CEN Biotech, Hopital Antoine Beclere, Pileje
NCT04784182N/AJul 20, 2021Auburn University, University of Alabama, Birmingham
NCT04756544Phase 3Dec 17, 2020Medical University of Lodz
NCT04366089Phase 2Mar 26, 2020University of Roma La Sapienza
NCT04555434N/AOct 1, 2019Hallym University
NCT04065503Early Phase 1 (Phase 1)Sep 30, 2019Lallemand SAS, University of Florida
NCT03940612N/AMay 1, 2019Synbio Tech, University of Science Malaysia
NCT03801655N/AAug 15, 2018University of Oxford
NCT03277586Phase 3May 29, 2018Queen's University, Belfast
NCT02838043Phase 3Aug 1, 2016Lallemand SAS, McMaster University, Queen's University, Belfast
NCT02417454Phase 3Sep 1, 2015Lallemand SAS, McMaster University
NCT02545634Phase 4Jun 1, 2015Acadia University, Lallemand SAS
NCT02334644Phase 4Apr 1, 2015Hamilton Health Sciences Corporation, Lallemand SAS, McMaster University
NCT02215304N/AJun 1, 2014Lallemand SAS, ProbiSearch SL, Universidad Autonoma de Madrid
NCT01853124Phase 3Nov 1, 2013Canadian Institutes of Health Research (CIHR), Dalhousie University, Lallemand SAS, University of Calgary, University of Montreal, University of Ottawa, University of Toronto, University of Western Ontario
NCT01941160Phase 1/Phase 2 (Phase 2)Aug 1, 2013KGK Science Inc., Lallemand SAS
NCT02335632Phase 4Dec 1, 2012Hallym University
NCT01709825N/ASep 1, 2012Lallemand SAS, University of Florida
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (33)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Lallemand SASFor profit11252008
McMaster UniversityAcademic/Hospital3222015
Hallym UniversityAcademic/Hospital2222012
Queen's University, BelfastAcademic/Hospital2212016
University of FloridaAcademic/Hospital2222012
University of TorontoAcademic/Hospital2122009
Acadia UniversityAcademic/Hospital1112015
Auburn UniversityAcademic/Hospital1112021
BiofortisFor profit1012008
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012013
CEN BiotechFor profit1112021
Chr HansenFor profit1012006
Dalhousie UniversityAcademic/Hospital1012013
Hamilton Health Sciences CorporationAcademic/Hospital1012015
Hopital Antoine BeclereAcademic/Hospital1012021
KGK Science Inc.For profit1112013
Medical University of LodzAcademic/Hospital1112020
National Science Centre, PolandGovernment1012024
PilejeAcademic/Hospital1012021
Poznan UniversityAcademic/Hospital1112022
33 organizations
Page 1 / 2